RegenLab USA Opens New R&D and Manufacturing Facility in Jersey City
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Jersey City, 13 June 2025 – RegenLab USA, a leading provider of medical devices in autologous regenerative medicine, has officially inaugurated a state-of-the-art facility dedicated to research, development, and the manufacturing of advanced medical technologies. This new opening further consolidates New Jersey’s position as a key hub in the life sciences sector.
The Jersey City site is designed to accelerate the company’s innovations across various therapeutic areas, including aesthetics, orthopaedics, gynaecology, and tissue engineering. It builds on RegenLab’s patented technology for blood component separation, supported by an extensive portfolio of over 150 international patents and more than 300 scientific publications.
This American hub forms part of RegenLab’s global expansion strategy. The company already operates a manufacturing site in the United States since 2021, alongside facilities in Switzerland and an upcoming location in France.
A Catalyst for Local Innovation
The establishment of this cutting-edge centre in Jersey City underscores RegenLab USA’s commitment to bringing research and manufacturing closer to its American customers. The initiative also aligns with New Jersey’s broader efforts to attract and retain businesses in the life sciences sector.
Growth Opportunities Ahead
With this significant investment, RegenLab USA aims to strengthen its development of platelet-rich plasma (PRP) treatments, including the already well-recognised RegenKit® BCT range, known for its effectiveness and ease of use.
The facility is expected to meet increasing demand for personalised medical solutions, while also creating highly skilled jobs and enhancing the company’s industrial presence in the region.
RegenLab USA has taken a major strategic step by launching its new R&D and manufacturing site in Jersey City. The initiative not only boosts the company’s footprint in the United States but also contributes to the New Jersey region’s momentum in the biotech sector.